Japan launches 3-Year safety watch for Crohn's fistula injection
NCT ID NCT05113095
Summary
This study is monitoring the long-term safety and effectiveness of a cell-based injection (darvadstrocel) for treating complex anal fistulas in people with Crohn's disease. It will follow about 275 patients in Japan for three years after they receive the injection as part of their standard care. The main goals are to track any side effects and see if the treatment helps close the fistulas and improve patients' quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Takeda selected site
RECRUITINGTokyo, Tokyo, Japan
Conditions
Explore the condition pages connected to this study.